Eden, Crucell ink manufacturing agreement

RESEARCH TRIANGLE PARK, N.C. Watson Pharmaceuticals biotech subsidiary Eden Biodesign has signed a manufacturing agreement with Dutch biotech company Crucell that will give Watson access to Crucell’s cell line technology, the two companies announced Wednesday.

Under the agreement, Eden will provide process development and current good manufacturing practice services using Crucell’s PER.C6 technology to licensees using the technology to develop vaccines and gene therapies.

“We are delighted to strengthen our relationship with Crucell and to be able to offer Eden Biodesign’s services to Crucell’s PER.C6 licensees,” Eden CEO Crawford Brown said. “We have demonstrated that the combination of Crucell’s proven and valuable technology and Eden Biodesign’s expertise in vaccine and gene therapy development and manufacturing delivers tremendous value to our customers by accelerating progression of products into and through clinical development, while maintaining the ability to scale up production and achieve highly attractive cost of goods.”